NEO · NeoGenomics, Inc. · Stock research

.# NEO — NeoGenomics, Inc.

Current Thesis

The oncology-diagnostics turnaround at NeoGenomics has moved from anticipated to confirmed, and the tape has re-rated accordingly: shares printed a fresh 52-week high of $15.57 in mid-July and closed 2026-07-17 near $14.61, roughly +25% year-to-date and +111% over twelve months. The engine is mix, not volume heroics — next-generation sequencing grew 26% year-over-year in Q1 2026 against 11% total revenue growth, and now contributes about a third of clinical revenue, which is where the incremental gross margin lives. Two things changed since the last read. First, the catalyst moved forward: management confirmed Q2 results for after the close on 2026-07-28, not early August, which pulls the binary event inside two weeks and makes the days immediately before it an entry blackout for anything that is not an earnings bet. Second, the analyst band re-set above the price. TD Cowen took its target from $14 to $19 on 2026-07-13 and BofA from $11 to $16 the same day, lifting the consensus target to roughly $15.67 against 8 Buy / 4 Hold / 0 Sell. For most of June the stock traded above the street's average target, which forced continuation to come from estimate revisions; that gap has closed, and the name now trades at a modest discount to consensus with the revision trend still one-directional.

The narrative leg an investor is buying is a mix-shift margin inflection at a reference lab that was left for dead: legacy clinical testing funds the network, while NGS, minimal residual disease (RaDaR ST), and liquid biopsy (PanTracer LBx) carry the growth and the price. The 2026-07-09 launch of PTEN IHC CDx — the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma, paired to AstraZeneca's TRUQAP (capivasertib) — is the newest evidence that the pivot from commodity testing to therapy-linked diagnostics is real rather than a slide-deck ambition. Companion diagnostics carry pharma-linked pull-through and regulatory moat that a generic panel does not.

What holds the read to a low-conviction stance is timing, not thesis. The theme is ACCELERATING, momentum is confirmed by a new high, and strength is the setup in this framework — but a print six trading days out with RSI near 74 and price within 6% of its high is the specific configuration where a fresh chase is a coin flip on guidance rather than a bet on structure.

Bullish and bearish views on NeoGenomics, Inc.

The model's bull view on NeoGenomics, Inc. (NEO), in brief: Mix compounding well above the base. Q1 2026 (reported 2026-04-28): revenue $186.7M, +11% YoY, a Q1 record, versus $184.53M consensus. Clinical revenue +14%. NGS +26% YoY, now roughly one-third of clinical. Clinical volumes +6% and average unit price +8% moved together — demand… The bear view: The margin structure is thin enough to break on one line item. Both cases follow in full.

Bull Case

• Mix compounding well above the base. Q1 2026 (reported 2026-04-28): revenue $186.7M, +11% YoY, a Q1 record, versus $184.53M consensus. Clinical revenue +14%. NGS +26% YoY, now roughly one-third of clinical. Clinical volumes +6% and average unit price +8% moved together — demand and pricing both constructive, which is rare in a reference-lab model where volume growth usually comes at price.
• First FDA-approved IHC companion diagnostic in prostate (2026-07-09). PTEN IHC CDx identifies PTEN protein loss to select patients for AstraZeneca's TRUQAP, using the VENTANA PTEN (SP218) RxDx assay. Turnaround of one to two days, available standalone or bundled into NEO PanTracer Pro for prostate. Shares rose ~3.4% on the launch. This is a therapy-linked, regulator-gated revenue line, not a me-too panel.
• RaDaR ST attach economics. Relaunched 2026-02-25 with detection to 1 ppm after Natera withdrew its appeal in December 2025, leaving the asserted claims invalidated. Management reports ~29% of prior RaDaR 1.0 customers have re-ordered RaDaR ST, and 34% of RaDaR ST orders pull additional NeoGenomics tests — the attach rate is the real economics of an MRD franchise.
• Liquid-biopsy reimbursement live. PanTracer LBx received CMS/MolDX Medicare coverage in March 2026, addressing a $3–5B liquid-biopsy market; PanTracer Pro extends the coordinated tumor workup.
• Guide raised, EBITDA inflecting. FY2026 guidance lifted to $797M–$803M revenue and $55M–$57M adjusted EBITDA, +27–31% YoY; Q1 adjusted EBITDA +27% YoY. Cadence guided to ~9% growth in Q2, 9–10% in Q3, above 10% in Q4 — an accelerating shape into the back half.
• Revisions running one way. TD Cowen $14→$19 Buy on 2026-07-13 (Dan Brennan, diagnostics-group Q2 preview citing volume growth and improving pricing); BofA $11→$16 the same day; Leerink Outperform $25 post-Q1; Needham Buy $15. Consensus target ~$15.67, range $11–$25.
• Board signal on data/AI (2026-06-25). Carolyn Starrett, CEO of Flatiron Health from April 2021 to September 2025, joined as an independent director. Flatiron is the reference asset in oncology real-world data; the appointment points at a data-monetization leg beyond test volume.
• Convert refinanced the debt wall. The 2026-06-17 $275M 0.75% notes due July 2032 repurchase ~$276M principal of the 0.25% 2028 converts for ~$263M, fund ~$25M of capped calls at a $20.98 cap (100% premium) and up to $25M of buyback. Conversion price $14.16 — already cleared by the current price.

Bear Case

• The margin structure is thin enough to break on one line item. The raised guide implies roughly $56M of adjusted EBITDA on ~$800M of revenue — about a 7% margin. In a high-volume, low-margin testing model, a few points of reimbursement or payer-mix pressure swings the quarter. There is no cushion for a bad Medicare rate cycle.
• Earnings on 2026-07-28 is the binary. The stock is priced for a guidance raise. A reiterated full-year range, or NGS growth decelerating toward the high teens, re-marks the entire re-rating rather than trimming it. Q2 was guided at ~9% growth — the softest quarter of the year — so the beat has to come from mix and commentary, not headline revenue.
• Natera still owns the MRD commercial lead. Signatera holds the volume and the payer relationships despite the patent loss. RaDaR ST re-order rates in the high twenties are early-stage traction, not share capture. If Q2 shows attach flattening, the highest-multiple part of the story stalls.
• Positioning is stretched. RSI around 74 into a print, price within roughly 6% of the $15.57 high, and a move of over 200% off the $4.72 52-week low. Names in that configuration do not need bad news to give back 15%; they need an in-line quarter.
• Bull case now requires the top of the range. Leerink's $25 assumes MRD and liquid-biopsy beat for several consecutive quarters. At $14.61 against a ~$15.67 consensus, the near-term upside to the average target is roughly 7% — the asymmetry has compressed versus where it stood at $10.
• Better-capitalized competition. Exact Sciences, Guardant, Tempus and Natera all fund oncology-diagnostics R&D from larger balance sheets. NeoGenomics competes on breadth of the coordinated workup rather than on spend.

Setup & Price Structure

Price closed 2026-07-17 near $14.61 after an intraday range of $14.35–$15.04, with the 52-week high at $15.57 set earlier in the week. The structural anchors stack cleanly: the prior all-time high at $13.74 was taken out in June and now serves as the breakout shelf; the $14.16 convertible conversion price sits just under current trade and is a natural magnet from below; the $20.98 capped-call cap defines the dilution ceiling and, in a melt-up, the plausible upside magnet. The 52-week range is $4.72–$15.57.

RSI near 74 is overbought but not blowoff — this is the middle of a trend, not the end of one. The relevant structural question is whether the $13.74–$14.16 zone holds on any pre-earnings shake, because that band is where the breakout is either confirmed as support or exposed as a failed extension. A slice straight through it before the print says the market is de-risking the guide in advance.

For a fresh position the timing is the problem. With results after the close on 2026-07-28, the three trading days before — roughly from 2026-07-23 — are an entry blackout under any framework that does not want to own a guidance gamble. Momentum is real, the theme is ACCELERATING, and the analyst band re-rating above spot on 2026-07-13 is genuine confirmation, but sizing into a binary six sessions out on a 7%-EBITDA-margin business is paying full price for the setup and the event at once.

Catalyst Calendar (next 30 days)

• 2026-07-28 (confirmed) — Q2 2026 results after the US close, conference call 4:30 p.m. ET. The re-mark: NGS growth rate versus the +26% Q1 comp, clinical volume/price split, RaDaR ST re-order and attach metrics, and whether the $797M–$803M / $55M–$57M full-year guide moves up again. Guided Q2 growth was ~9%.
• Late July / early August — 10-Q filing following the print; watch cash, the post-refinancing debt schedule, and any disclosure on the up-to-$25M buyback authorization.
• No FDA/PDUFA or MolDX decision dates currently scheduled inside the window. The July 28 print is the only hard-dated event.

Elapsed catalysts

• 2026-07-23 (est.) — start of the practical entry blackout ahead of the print; three trading days before results. (passed 5d ago)
• Ongoing through August — PTEN IHC CDx commercial ramp commentary and any additional companion-diagnostic partnerships; the 2026-07-09 launch is too new to appear meaningfully in Q2 revenue but should show up in guidance language. (passed 19d ago)

What Would Change Our Mind

• Structural break: a weekly close below $13.70 gives back the June breakout above the prior $13.74 all-time high and the $14.16 convertible conversion level, turning the move into a failed extension. That is the level that grades the thesis.
• Growth deceleration: NGS growth printing below roughly 20% YoY on 2026-07-28, versus +26% in Q1. Mix shift is the entire margin story; if it slows, the multiple has nothing to hold.
• Guide unchanged or trimmed: the full-year range staying at $797M–$803M, or adjusted EBITDA guidance being reiterated rather than raised, would say the Q1 raise was the peak of the revision cycle.
• MRD attach stalling: RaDaR ST re-order or attach rates flat versus the ~29% / 34% disclosed metrics, or explicit commentary on Signatera taking share.
• Reimbursement shock: an adverse Medicare rate action on NGS panels or MolDX policy change on PanTracer LBx — the 7% EBITDA margin has no absorption capacity.
• Theme rolling over: medtech-diagnostics flipping from ACCELERATING to SATURATED, visible in peers (Exact Sciences, Guardant, Natera, Tempus) failing to hold their own breakouts while NEO stalls at the highs.

Correlation Notes

• Direct MRD/liquid-biopsy peers: Natera (NTRA) is the read-across for MRD volume and payer traction; Guardant Health (GH) for liquid biopsy; Exact Sciences (EXAS) for screening-side reimbursement sentiment. NEO trades with this group on Medicare and MolDX headlines regardless of company-specific news.
• Precision-oncology tools: Tempus AI (TEM) and Adaptive Biotechnologies (ADPT) share the sequencing-plus-data narrative; ADPT is the cleaner tools-side expression of the same MRD theme and often leads NEO on theme-level rotations.
• Pharma linkage: the PTEN IHC CDx revenue line is tied to AstraZeneca's TRUQAP uptake in prostate adenocarcinoma. TRUQAP prescription trends are a leading indicator for that specific segment, though it is a small share of total revenue near-term.
• Rate sensitivity: as an unprofitable-on-GAAP, thin-EBITDA growth name with a 2032 convert on the balance sheet, NEO carries above-market duration risk. A hawkish macro turn compresses it faster than diversified diagnostics peers.
• Index context: small/mid-cap healthcare (XBI, IHI) beta is material — the name has historically amplified biotech-complex risk appetite in both directions.